title: Comparative review of the blood pressure-lowering and cardiovascular benefits of telmisartan and perindopril.
abstract: Hypertension is a major cardiovascular (CV) risk factor, and blood pressure (BP)-lowering treatment substantially reduces the risk. This review compares the available clinical evidence from the BP-lowering and CV-outcome studies of telmisartan and perindopril, which are among the most intensively studied members of their respective classes. The PubMed database was searched for telmisartan and perindopril publications meeting the following criteria: 1) head-to-head comparison trials for BP lowering; and 2) CV-outcome studies (ie, ones with a CV event, mortality, or hospitalization outcome) in patients with CV risk factors but without heart failure. In comparative trials, telmisartan treatment resulted in significantly higher reduction in trough BP and mean ambulatory diastolic BP for the last 8 hours of the dosing interval compared with perindopril. In mainly placebo-controlled CV-outcome studies in patients with hypertension, CV benefits with perindopril were associated with large reductions in BP. There were no CV outcome studies with telmisartan in patients with hypertension. The beyond-BP-lowering CV-protective benefits of telmisartan were demonstrated in the active-controlled ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) trial, which included patients with controlled BP at baseline. In general, the trials discussed in this review reinforce the fact that perindopril and telmisartan are two long-acting antihypertensive drugs that reduce BP over 24 hours, and are the best-evidenced drugs in their class with proven CV protection. It is also clear that the benefits are not a "class effect", and vary between the different drugs within each class. Hence, the best approach for treatments tailored to individual patient needs should be evidence-based specific drugs, rather than a drug-class recommendation for achieving therapeutic targets.
authors.affiliation: Centre for Epidemiological Studies and Clinical Trials, Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, People's Republic of China.
authors.forename: Ji-Guang
authors.initials: JG
authors.lastname: Wang
authors.affiliation: Boehringer Ingelheim, Sydney, NSW, Australia.
authors.forename: Eduardo
authors.initials: E
authors.lastname: Pimenta
authors.affiliation: Boehringer Ingelheim Pharma, Biberach an der Riss, Germany.
authors.forename: Frank
authors.initials: F
authors.lastname: Chwallek
mesh_terms: D047228:Angiotensin II Type 1 Receptor Blockers / Q000009:adverse effects / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000009:adverse effects / Q000627:therapeutic use*; D001565:Benzoates / Q000009:adverse effects / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects*; D006801:Humans; D006973:Hypertension / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D020913:Perindopril / Q000009:adverse effects / Q000627:therapeutic use*; D011314:Preventive Health Services; D018570:Risk Assessment; D012307:Risk Factors; D000077333:Telmisartan; D016896:Treatment Outcome
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D001562:Benzimidazoles; D001565:Benzoates; D000077333:Telmisartan; D020913:Perindopril
keywords: angiotensin-converting enzyme inhibitor; angiotensin-receptor blocker; antihypertensive therapy; clinical outcome; hypertension; renin–angiotensin system inhibitors
references.citation: J Am Soc Nephrol. 2004 Jan;15 Suppl 1:S71-6
references.pmid: 14684677
references.citation: J Hum Hypertens. 2002 Dec;16(12):865-73
references.pmid: 12522468
references.citation: J Hypertens Suppl. 2009 Jul;27(5):S23-9
references.pmid: 19587551
references.citation: CMAJ. 2013 Sep 3;185(12):1035-41
references.pmid: 23836857
references.citation: Lancet. 2007 Apr 7;369(9568):1208-19
references.pmid: 17416265
references.citation: Cardiovasc Diabetol. 2007 Oct 02;6:28
references.pmid: 17910747
references.citation: J Hypertens Suppl. 1993 Apr;11(3):S49-52
references.pmid: 8315520
references.citation: Lancet. 2003 Sep 6;362(9386):782-8
references.pmid: 13678872
references.citation: Lancet. 2005 Sep 10-16;366(9489):895-906
references.pmid: 16154016
references.citation: Zhonghua Xin Xue Guan Bing Za Zhi. 2009 Oct;37(10):908-12
references.pmid: 20137542
references.citation: Drugs. 1991 Jul;42(1):90-114
references.pmid: 1718688
references.citation: Ther Adv Cardiovasc Dis. 2012 Apr;6(2):81-91
references.pmid: 22528743
references.citation: Diabetes Care. 2013 Jan;36 Suppl 1:S11-66
references.pmid: 23264422
references.citation: J Hum Hypertens. 2008 May;22(5):338-45
references.pmid: 18305548
references.citation: Core Evid. 2007 Mar 31;2(1):63-79
references.pmid: 21221198
references.citation: Circulation. 2006 Mar 7;113(9):1213-25
references.pmid: 16476843
references.citation: Lancet Neurol. 2010 Aug;9(8):767-75
references.pmid: 20621562
references.citation: Drugs. 2001;61(6):867-96
references.pmid: 11398915
references.citation: N Engl J Med. 2008 Sep 18;359(12):1225-37
references.pmid: 18753639
references.citation: BMJ. 2011 Jan 04;344:d7541
references.pmid: 22218098
references.citation: Drugs. 2001;61(10):1501-29
references.pmid: 11558835
references.citation: Stroke. 2009 May;40(5):1938-40
references.pmid: 19038906
references.citation: Hypertension. 2007 Jul;50(1):181-8
references.pmid: 17502490
references.citation: Am J Geriatr Cardiol. 2006 May-Jun;15(3):151-60
references.pmid: 16687967
references.citation: Clinicoecon Outcomes Res. 2011;3:47-54
references.pmid: 21935332
references.citation: J Hypertens. 2013 Jul;31(7):1281-357
references.pmid: 23817082
references.citation: Ann Intern Med. 1995 Dec 1;123(11):888-9
references.pmid: 7486476
references.citation: Lancet. 2008 Aug 16;372(9638):547-53
references.pmid: 18707986
references.citation: Ann Intern Med. 1995 Dec 1;123(11):873-7
references.pmid: 7486471
references.citation: Eur Heart J. 2012 Aug;33(16):2088-97
references.pmid: 22511654
references.citation: J Pharmacol Exp Ther. 2002 Sep;302(3):1089-95
references.pmid: 12183667
references.citation: J Am Coll Cardiol. 2005 Sep 6;46(5):821-6
references.pmid: 16139131
references.citation: Eur Heart J. 2006 Oct;27(19):2338-45
references.pmid: 16963472
references.citation: Lancet. 2004 Jun 19;363(9426):2022-31
references.pmid: 15207952
references.citation: J Hypertens. 2009 Nov;27(11):2121-58
references.pmid: 19838131
references.citation: Lancet. 2001 Oct 20;358(9290):1305-15
references.pmid: 11684211
references.citation: Lancet. 2007 Sep 8;370(9590):804-5
references.pmid: 17765962
references.citation: J Manag Care Pharm. 2007 Oct;13(8 Suppl B):9-20
references.pmid: 17970613
references.citation: BMJ. 2011 Apr 26;342:d2234
references.pmid: 21521728
references.citation: J Am Coll Cardiol. 2013 Jan 15;61(2):131-42
references.pmid: 23219304
references.citation: Drugs. 2006;66(1):51-83
references.pmid: 16398568
references.citation: J Am Coll Cardiol. 2005 Jun 7;45(11):1832-9
references.pmid: 15936615
references.citation: J Hum Hypertens. 2009 May;23(5):339-49
references.pmid: 18987649
references.citation: Lancet. 2007 Sep 8;370(9590):829-40
references.pmid: 17765963
references.citation: N Engl J Med. 2008 May 1;358(18):1887-98
references.pmid: 18378519
references.citation: Circulation. 2009 Oct 20;120(16):1598-605
references.pmid: 19805653
references.citation: Lancet. 2004 Jun 19;363(9426):2049-51
references.pmid: 15207957
references.citation: Cardiovasc Res. 2007 Jan 1;73(1):237-46
references.pmid: 17140552
references.citation: Patient Prefer Adherence. 2012;6:1-9
references.pmid: 22272064
references.citation: Hypertension. 2005 Jul;46(1):156-61
references.pmid: 15939805
references.citation: Int Heart J. 2009 Jul;50(4):501-12
references.pmid: 19609054
references.citation: N Engl J Med. 2000 Jan 20;342(3):145-53
references.pmid: 10639539
references.citation: N Engl J Med. 2008 Apr 10;358(15):1547-59
references.pmid: 18378520
references.citation: J Hypertens. 2008 Jul;26(7):1282-9
references.pmid: 18550998
references.citation: Lancet. 2008 Sep 27;372(9644):1174-83
references.pmid: 18757085
references.citation: Arch Intern Med. 2006 Mar 27;166(6):659-66
references.pmid: 16567606
references.citation: Stroke. 2007 May;38(5):1655-711
references.pmid: 17431204
references.citation: Am J Cardiol. 2002 Jan 24;89(2A):3A-9A; discussion 10A
references.pmid: 11835903
references.citation: Vasc Health Risk Manag. 2006;2(2):117-24
references.pmid: 17319455
references.citation: Int J Clin Pract Suppl. 2004 Dec;(145):50-4
references.pmid: 15617460
references.citation: J Hypertens Suppl. 2005 Apr;23(1):S9-17
references.pmid: 15821452
references.citation: Lancet. 2001 Sep 29;358(9287):1033-41
references.pmid: 11589932
references.citation: Hypertension. 2003 Jun;41(6):1281-6
references.pmid: 12719441
references.citation: J Clin Epidemiol. 1995 Jan;48(1):71-9
references.pmid: 7853050
references.citation: JAMA. 2011 Nov 16;306(19):2137-44
references.pmid: 22089721
references.citation: Eur Heart J. 2012 Jul;33(14):1787-847
references.pmid: 22611136
references.citation: Lancet. 2001 Sep 29;358(9287):1026-7
references.pmid: 11589927
references.citation: J Clin Hypertens (Greenwich). 2012 Apr;14(4):206-15
references.pmid: 22458741
references.citation: Lancet. 2003 Nov 8;362(9395):1527-35
references.pmid: 14615107
references.citation: Blood Press Monit. 1999 Jun-Aug;4(3-4):181-4
references.pmid: 10490872
references.citation: N Engl J Med. 2008 Dec 4;359(23):2417-28
references.pmid: 19052124